Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.

Show other versions (1)

Vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR2) are the key factors mediating neo-vascularization. They are often coexpressed in breast cancer. Sex steroids may stimulate angiogenesis via the estrogen receptor (ER) pathway. We investigated to...

Full description

Bibliographic Details
Main Authors:	Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A
Format:	Journal article
Language:	English
Published:	2010

Similar Items

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
by: Mele, T, et al.
Published: (2010)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
by: Fox, S, et al.
Published: (2011)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
by: Fox, S, et al.
Published: (2011)

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
by: Generali, D, et al.
Published: (2009)

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
by: Generali, D, et al.
Published: (2009)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
by: Generali, D, et al.
Published: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
by: Generali, D, et al.
Published: (2007)

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
by: Generali, D, et al.
Published: (2008)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
by: Generali, D, et al.
Published: (2006)

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
by: Generali, D, et al.
Published: (2006)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
by: Generali, D, et al.
Published: (2006)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
by: Generali, D, et al.
Published: (2008)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
by: Fox, S, et al.
Published: (2006)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
by: Generali, D, et al.
Published: (2011)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
by: Foroni, C, et al.
Published: (2009)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
by: Allevi, G, et al.
Published: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
by: Allevi, G, et al.
Published: (2013)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
by: Andreis, D, et al.
Published: (2016)

The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
by: Milani, M, et al.
Published: (2009)

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
by: A Ianza, et al.
Published: (2020-06-01)

Vitamin C-driven epirubicin loading into liposomes
by: Lipka D, et al.
Published: (2013-09-01)

Epirubicin-induced Kounis syndrome
by: Hui-zhu Liang, et al.
Published: (2021-03-01)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
by: Zhen-Ling Liu, et al.
Published: (2023-05-01)

Biomarkers of anti-angiogenic therapy in breast cancer
by: Mehta, S
Published: (2014)

Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells.
by: Sabry M Attia, et al.
Published: (2016-01-01)

Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.
by: Meser M Ali, et al.
Published: (2010-01-01)

WITHDRAWN: Tamoxifen for early breast cancer.
by: Clarke, M
Published: (2008)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
by: Andreas Venizelos, et al.
Published: (2022-08-01)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
by: Kerstin Wimmer, et al.
Published: (2023-11-01)

Polyphosphazene-Based Nanocarriers for the Release of Camptothecin and Epirubicin
by: Javier Pérez Quiñones, et al.
Published: (2022-01-01)

Effect of Epirubicin Against Glioma Initiating Cells
by: Atsushi Nakajima, et al.
Published: (2020-11-01)

GENETIC CRITERIA FOR ANTI-ANGIOGENIC THERAPY FOR TREATMENT OF DIABETIC MACULAR EDEMA
by: A. Z. Fursova, et al.
Published: (2019-02-01)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
by: Yuntao Wang MS, et al.
Published: (2021-03-01)

Screening of oral tamoxifen ocular toxicity in patients with breast cancer
by: Ahmed Tharwat, et al.
Published: (2022-01-01)

Modern breast cancer therapy: from tamoxifen to T-cell engineering
by: Yu. A. Shevchenko, et al.
Published: (2022-11-01)

Correction: Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells.
by: Sabry M Attia, et al.
Published: (2016-01-01)

Nephrotoxicity of Anti-Angiogenic Therapies
by: Margaux Van Wynsberghe, et al.
Published: (2021-04-01)

Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas.
by: Passalidou, E, et al.
Published: (2002)

Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas.
by: Passalidou, E, et al.
Published: (2002)

Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta
by: Adnan İncebıyık, et al.
Published: (2018-02-01)